clinical trial · NCT07347600
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche·—·recruiting·n = 500
Locally Advanced Breast CancerMetastatic Breast CancerInavolisibPalbociclibFulvestrant
brief summary
The main purpose of this study is to evaluate the effectiveness of inavolisib based regimen in participants with endocrine-resistant, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer (LA/mBC), following on or after completing adjuvant endocrine therapy in routine clinical practice in China.
started
Jan 21, 2026
primary completion
Dec 31, 2028
completion
Sep 9, 2029
last updated
Apr 20, 2026
official title
A Prospective Non-interventional Study to Evaluate the Effectiveness and Safety of Inavolisib in Patients With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (reaINAVO)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol